BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 252 filers reported holding BIO-TECHNE CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $10,168,000 | -35.3% | 51,210 | -52.8% | 0.14% | -44.8% |
| Q4 2018 | $15,711,000 | -48.2% | 108,563 | -27.0% | 0.25% | -40.2% |
| Q3 2018 | $30,343,000 | +32.6% | 148,660 | -3.9% | 0.42% | +24.4% |
| Q2 2018 | $22,879,000 | +10.1% | 154,640 | +12.4% | 0.34% | +6.7% |
| Q1 2018 | $20,773,000 | +10.2% | 137,529 | -5.5% | 0.32% | +14.1% |
| Q4 2017 | $18,853,000 | +5.1% | 145,530 | -1.9% | 0.28% | -1.1% |
| Q3 2017 | $17,939,000 | +26.2% | 148,393 | +22.6% | 0.28% | +22.4% |
| Q2 2017 | $14,218,000 | +13.6% | 121,008 | -1.7% | 0.23% | +16.9% |
| Q1 2017 | $12,517,000 | -55.4% | 123,141 | -54.9% | 0.20% | -12.2% |
| Q4 2016 | $28,048,000 | +80.2% | 272,766 | +91.9% | 0.22% | -13.6% |
| Q3 2016 | $15,565,000 | -3.3% | 142,143 | -0.4% | 0.26% | -6.5% |
| Q2 2016 | $16,095,000 | +18.6% | 142,724 | -0.6% | 0.28% | +16.5% |
| Q1 2016 | $13,572,000 | +55.2% | 143,587 | +47.8% | 0.24% | +45.7% |
| Q4 2015 | $8,745,000 | -30.9% | 97,162 | -29.0% | 0.16% | -23.2% |
| Q3 2015 | $12,650,000 | -10.1% | 136,815 | -4.2% | 0.21% | -1.4% |
| Q2 2015 | $14,065,000 | -5.7% | 142,832 | -4.0% | 0.21% | -3.2% |
| Q1 2015 | $14,914,000 | -9.4% | 148,711 | -16.5% | 0.22% | -9.8% |
| Q4 2014 | $16,464,000 | – | 178,179 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |